Histone methylation at H3K9: Evidence for a restrictive epigenome in schizophrenia

Schizophrenia Research

Volumn 149, Issue 1-3, 2013, Pages 15-20

  Chase, Kayla A ^a   Gavin, David P ^a,b   Guidotti, Alessandro ^a   Sharma, Rajiv P ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Chromatin; Epigenetics; Histone methylation; Lymphocyte; Postmortem Brain; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; HISTONE H3; HISTONE METHYLTRANSFERASE; MESSENGER RNA; MOOD STABILIZER; NEUROLEPTIC AGENT; PROTEIN G9A; PROTEIN GLP; PROTEIN SETDB1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; DISEASE DURATION; DISEASE EXACERBATION; DOWN REGULATION; EPIGENETICS; FAMILY HISTORY; FEMALE; GENE EXPRESSION; HISTONE METHYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PARIETAL CORTEX; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTIVE EPIGENOME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

CHROMATIN; EPIGENETICS; HISTONE METHYLATION; LYMPHOCYTE; POSTMORTEM BRAIN; SCHIZOPHRENIA;

ADULT; CEREBRAL CORTEX; EPIGENOMICS; FEMALE; GENE EXPRESSION REGULATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LINEAR MODELS; LYMPHOCYTES; LYSINE; MALE; METHYLATION; MIDDLE AGED; POSTMORTEM CHANGES; PROTEIN METHYLTRANSFERASES; PSYCHIATRIC STATUS RATING SCALES; RNA, MESSENGER; SCHIZOPHRENIA;

EID: 84881218309     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2013.06.021     Document Type: Article

References (49)

1. Akbarian S., Kim J.J., Potkin S.G., Hagman J.O., Tafazzoli A., Bunney W.E., Jones E.G. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 1995, 52(4):258-266.
2. Andersen R.A., Buneo C.A. Sensorimotor integration in posterior parietal cortex. Adv. Neurol. 2003, 93:159-177.
3. Arango C., Kirkpatrick B., Buchanan R.W. Neurological signs and the heterogeneity of schizophrenia. Am. J. Psychiatry 2000, 157(4):560-565.
4. Benes F.M., Lim B., Matzilevich D., Walsh J.P., Subburaju S., Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(24):10164-10169.
5. Buchanan R.W., Carpenter W.T. Domains of psychopathology: an approach to the reduction of heterogeneity in schizophrenia. J. Nerv. Ment. Dis. 1994, 182(4):193-204.
6. Chase K.A., Sharma R.P. Nicotine induces chromatin remodelling through decreases in the methyltransferases GLP, G9a, Setdb1 and levels of H3K9me2. Int. J. Neuropsychopharmacol. 2012, 1-10.
7. Cheung I., Shulha H.P., Jiang Y., Matevossian A., Wang J., Weng Z., Akbarian S. Developmental regulation and individual differences of neuronal H3K4me3 epigenomes in the prefrontal cortex. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(19):8824-8829.
8. Cohen Y.E., Andersen R.A. A common reference frame for movement plans in the posterior parietal cortex. Nat. Rev. Neurosci. 2002, 3(7):553-562. 10.1038/nrn873.
9. Fatemi S.H., Stary J.M., Earle J.A., Araghi-Niknam M., Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr. Res. 2005, 72(2-3):109-122.
10. Fox J.H., Barber D.S., Singh B., Zucker B., Swindell M.K., Norflus F., Buzescu R., Chopra R., Ferrante R.J., Kazantsev A., Hersch S.M. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation. J. Neurochem. 2004, 91(2):413-422.
11. Freedman B.J. The subjective experience of perceptual and cognitive disturbances in schizophrenia. A review of autobiographical accounts. Arch. Gen. Psychiatry 1974, 30(3):333-340.
12. Fritsch L., Robin P., Mathieu J.R., Souidi M., Hinaux H., Rougeulle C., Harel-Bellan A., Ameyar-Zazoua M., Ait-Si-Ali S. A subset of the histone H3 lysine 9 methyltransferases Suv39h1, G9a, GLP, and SETDB1 participate in a multimeric complex. Mol. Cell 2010, 37(1):46-56.
13. Gavin D.P., Kartan S., Chase K., Grayson D.R., Sharma R.P. Reduced baseline acetylated histone 3 levels, and a blunted response to HDAC inhibition in lymphocyte cultures from schizophrenia subjects. Schizophr. Res. 2008, 103(1-3):330-332.
14. Gavin D.P., Kartan S., Chase K., Jayaraman S., Sharma R.P. Histone deacetylase inhibitors and candidate gene expression: an in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J. Psychiatr. Res. 2009, 43(9):870-876.
15. Gavin D.P., Rosen C., Chase K., Grayson D.R., Tun N., Sharma R.P. Dimethylated lysine 9 of histone 3 is elevated in schizophrenia and exhibits a divergent response to histone deacetylase inhibitors in lymphocyte cultures. J. Psychiatry Neurosci. 2009, 34(3):232-237.
16. Geschwind N. Disconnexion syndromes in animals and man. I. Brain 1965, 88(2):237-294.
17. Guidotti A., Auta J., Davis J.M., Di-Giorgi-Gerevini V., Dwivedi Y., Grayson D.R., Impagnatiello F., Pandey G., Pesold C., Sharma R., Uzunov D., Costa E. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch. Gen. Psychiatry 2000, 57(11):1061-1069.
18. Hawrylycz M.J., Lein E.S., Guillozet-Bongaarts A.L., Shen E.H., Ng L., Miller J.A., et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 2012, 489(7416):391-399. 10.1038/nature11405; 10.1038/nature11405.
19. Impagnatiello F., Guidotti A.R., Pesold C., Dwivedi Y., Caruncho H., Pisu M.G., Uzunov D.P., Smalheiser N.R., Davis J.M., Pandey G.N., Pappas G.D., Tueting P., Sharma R.P., Costa E. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(26):15718-15723.
20. Issidorides M.R., Stefanis C.N., Varsou E., Katsorchis T. Altered chromatin ultrastructure in neutrophils of schizophrenics. Nature 1975, 258(5536):612-614.
21. Jayaraman S., Castro M., O'Sullivan M., Bragdon M.J., Holtzman M.J. Resistance to Fas-mediated T cell apoptosis in asthma. J. Immunol. 1999, 162(3):1717-1722.
22. Jindal R.D., Pillai A.K., Mahadik S.P., Eklund K., Montrose D.M., Keshavan M.S. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr. Res. 2010, 119(1-3):47-51.
23. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
24. Kleefstra T., Smidt M., Banning M.J., Oudakker A.R., Van Esch H., de Brouwer A.P., Nillesen W., Sistermans E.A., Hamel B.C., de Bruijn D., Fryns J.P., Yntema H.G., Brunner H.G., de Vries B.B., van Bokhoven H. Disruption of the gene Euchromatin Histone Methyl Transferase1 (Eu-HMTase1) is associated with the 9q34 subtelomeric deletion syndrome. J. Med. Genet. 2005, 42(4):299-306.
25. Kosower N.S., Gerad L., Goldstein M., Parasol N., Zipser Y., Ragolsky M., Rozencwaig S., Elkabetz E., Abramovitch Y., Lerer B. Constitutive heterochromatin of chromosome 1 and Duffy blood group alleles in schizophrenia. Am. J. Med. Genet. 1995, 60(2):133-138.
26. Krishnan S., Horowitz S., Trievel R.C. Structure and function of histone H3 lysine 9 methyltransferases and demethylases. ChemBioChem 2011, 12(2):254-263.
27. Manschreck T.C., Ames D. Neurologic features and psychopathology in schizophrenic disorders. Biol. Psychiatry 1984, 19(5):703-719.
28. McGhie A., Chapman J. Disorders of attention and perception in early schizophrenia. Br. J. Med. Psychol. 1961, 34:103-116.
29. Middleton F.A., Pato C.N., Gentile K.L., McGann L., Brown A.M., Trauzzi M., Diab H., Morley C.P., Medeiros H., Macedo A., Azevedo M.H., Pato M.T. Gene expression analysis of peripheral blood leukocytes from discordant sib-pairs with schizophrenia and bipolar disorder reveals points of convergence between genetic and functional genomic approaches. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005, 136B(1):12-25.
30. Nillesen W.M., Yntema H.G., Moscarda M., Verbeek N.E., Wilson L.C., Cowan F., Schepens M., Raas-Rothschild A., Gafni-Weinstein O., Zollino M., Vijzelaar R., Neri G., Nelen M., Bokhoven H., Giltay J., Kleefstra T. Characterization of a novel transcript of the EHMT1 gene reveals important diagnostic implications for Kleefstra syndrome. Hum. Mutat. 2011, 32(7):853-859.
31. Rosen C., Marvin R., Reilly J.L., Deleon O., Harris M.S., Keedy S.K., Solari H., Weiden P., Sweeney J.A. Phenomenology of first-episode psychosis in schizophrenia, bipolar disorder, and unipolar depression: a comparative analysis. Clin. Schizophr. Relat. Psychoses 2012, 6(3):145-151.
32. Ryu H., Lee J., Hagerty S.W., Soh B.Y., McAlpin S.E., Cormier K.A., Smith K.M., Ferrante R.J. ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103(50):19176-19181.
33. Schaefer A., Sampath S.C., Intrator A., Min A., Gertler T.S., Surmeier D.J., Tarakhovsky A., Greengard P. Control of cognition and adaptive behavior by the GLP/G9a epigenetic suppressor complex. Neuron 2009, 64(5):678-691.
34. Sharma R.P. Schizophrenia, epigenetics and ligand-activated nuclear receptors: a framework for chromatin therapeutics. Schizophr. Res. 2005, 72(2-3):79-90.
35. Sharma R.P. Blood chromatin as a biosensor of the epigenetic milieu: a tool for studies in living psychiatric patients. Epigenomics 2012, 4(5):551-559.
36. Sharma R.P., Rosen C., Kartan S., Guidotti A., Costa E., Grayson D.R., Chase K. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: preliminary results from a clinical population. Schizophr. Res. 2006, 88(1-3):227-231.
37. Sharma R.P., Grayson D.R., Gavin D.P. Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr. Res. 2008, 98(1-3):111-117.
38. Sharma R.P., Gavin D.P., Chase K.A. Heterochromatin as an incubator for pathology and treatment non-response: implication for neuropsychiatric illness. Pharmacogenomics J. 2012, 12(5):361-367.
39. Shinkai Y., Tachibana M. H3K9 methyltransferase G9a and the related molecule GLP. Genes Dev. 2011, 25(8):781-788.
40. Tachibana M., Ueda J., Fukuda M., Takeda N., Ohta T., Iwanari H., Sakihama T., Kodama T., Hamakubo T., Shinkai Y. Histone methyltransferases G9a and GLP form heteromeric complexes and are both crucial for methylation of euchromatin at H3-K9. Genes Dev. 2005, 19(7):815-826.
41. Torrey E.F. Neurological abnormalities in schizophrenic patients. Biol. Psychiatry 1980, 15(3):381-388.
42. Torrey E.F. Schizophrenia and the inferior parietal lobule. Schizophr. Res. 2007, 97(1-3):215-225. 10.1016/j.schres.2007.08.023.
43. Torrey E.F., Webster M., Knable M., Johnston N., Yolken R.H. The stanley foundation brain collection and neuropathology consortium. Schizophr. Res. 2000, 44(2):151-155.
44. Tzeng T.Y., Lee C.H., Chan L.W., Shen C.K. Epigenetic regulation of the Drosophila chromosome 4 by the histone H3K9 methyltransferase dSETDB1. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(31):12691-12696.
45. Vandesompele J., De Preter K., Pattyn F., Poppe B., Van Roy N., De Paepe A., Speleman F. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3(7). (RESEARCH0034).
46. Wang H., An W., Cao R., Xia L., Erdjument-Bromage H., Chatton B., Tempst P., Roeder R.G., Zhang Y. mAM facilitates conversion by ESET of dimethyl to trimethyl lysine 9 of histone H3 to cause transcriptional repression. Mol. Cell 2003, 12(2):475-487.
47. Wieselgren I.M., Lindstrom E., Lindstrom L.H. Symptoms at index admission as predictor for 1-5 year outcome in schizophrenia. Acta Psychiatr. Scand. 1996, 94(5):311-319.
48. Zee B.M., Levin R.S., Xu B., LeRoy G., Wingreen N.S., Garcia B.A. In vivo residue-specific histone methylation dynamics. J. Biol. Chem. 2010, 285(5):3341-3350.
49. Zhang Y., Reinberg D. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev. 2001, 15(18):2343-2360.